INO

Inovio Pharmaceuticals Inc

Apr 09 • 04:00PM ET

1.05

-0.04 -3.67 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NVAX PFE BNTX GSK JNJ AZN-D VXRT ARCT ADMA

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	0.42%	Shs Outstand	69.00M	Perf Week	-39.66%
Market Cap	72.55M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	68.80M	Perf Month	-39.31%
Enterprise Value	23.41M	PEG	-	EPS next Q	-0.35	Inst Own	47.79%	Short Float	15.64%	Perf Quarter	-37.13%
Income	-84.95M	P/S	1036.43	EPS this Y	36.69%	Inst Trans	17.97%	Short Ratio	7.66	Perf Half Y	-56.07%
Sales	0.07M	P/B	3.01	EPS next Y	58.12%	ROA	-89.14%	Short Interest	10.76M	Perf YTD	-39.66%
Book/sh	0.35	P/C	1.24	EPS next 5Y	-	ROE	-183.47%	52W High	2.98 -64.75%	Perf Year	-33.96%
Cash/sh	0.85	P/FCF	-	EPS past 3/5Y	49.51% 32.44%	ROIC	-277.23%	52W Low	1.05 0.00%	Perf 3Y	-88.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-81.47% -61.18%	Gross Margin	-4474.06%	Volatility	10.03% 6.59%	Perf 5Y	-99.00%
Dividend TTM	-	EV/Sales	334.43	EPS Y/Y TTM	51.48%	Oper. Margin	-132871.32%	ATR (14)	0.12	Perf 10Y	-99.05%
Dividend Ex-Date	-	Quick Ratio	1.40	Sales Y/Y TTM	-69.99%	Profit Margin	-130000.00%	RSI (14)	25.77	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	1.40	EPS Q/Q	109.14%	SMA20	-30.05%	Beta	1.68	Target Price	5.96
Payout	-	Debt/Eq	0.39	Sales Q/Q	-100.00%	SMA50	-35.08%	Rel Volume	2.10	Prev Close	1.09
Employees	112	LT Debt/Eq	0.27	Earnings	Mar 12 AMC	SMA200	-44.99%	Avg Volume	1.40M	Price	1.05
IPO	Dec 08, 1998	Option/Short	Yes / Yes	EPS/Sales Surpr.	116.76% -	Trades		Volume	2,919,304	Change	-3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-25	Initiated	Piper Sandler	Overweight	$5
May-14-24	Initiated	Stephens	Overweight	$20
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform	$4
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform	$2
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform	$5 → $4
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $10
Dec-29-21	Resumed	Jefferies	Hold	$8 → $6
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform	$9 → $8
Jun-24-21	Initiated	Jefferies	Hold	$9
Mar-23-21	Initiated	BofA Securities	Neutral	$13
Feb-12-21	Initiated	Oppenheimer	Outperform	$35
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral	$8
Sep-28-20	Upgrade	Maxim Group	Hold → Buy	$20
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell	$11
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral

Show Previous Ratings

Apr-02-26 08:55AM	INOVIO Announces Pricing of $17.5 Million Public Offering (PR Newswire) -35.06%
Apr-01-26 08:05PM	INOVIO Announces Proposed Public Offering (PR Newswire)
10:29AM	INOVIO to Participate in Upcoming Scientific Conference (PR Newswire)
Mar-30-26 03:47AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO (PR Newswire)
Mar-13-26 08:30AM	Inovio Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
11:07PM	Loading…
Mar-12-26 11:07PM	Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com)
04:47PM	Inovio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (PR Newswire)
Mar-09-26 08:05AM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
Mar-05-26 04:05PM	INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLASSIFICATION REVEALS ALLEGED REGULATORY SETBACK (PR Newswire)
08:05AM	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
Feb-26-26 09:16AM	Inovio Pharmaceuticals Spotlights INO-3107 BLA Acceptance, FDA Talks Ahead of Oct. 30 PDUFA Date (MarketBeat)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION (PR Newswire)
Feb-20-26 04:27AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO (PR Newswire)
08:05AM	Loading…
Feb-12-26 08:05AM	INOVIO to Participate in Upcoming Scientific and Investor Conferences (PR Newswire)
07:30AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights INO (Business Wire)
Dec-30-25 08:10AM	Inovio announces U.S. FDA accepted BLA for INO-3107 (TipRanks)
Dec-29-25 08:05AM	FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) (PR Newswire) -24.45%
Dec-19-25 04:05PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Nov-18-25 08:05AM	INOVIO to Participate in December Investor Conferences (PR Newswire)
Nov-14-25 12:00PM	Inovio (INO) Upgraded to Buy: Here's Why (Zacks) +5.13%
Nov-11-25 08:40AM	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire) -6.98%
12:00AM	Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-10-25 06:09PM	INOVIO Announces Proposed Public Offering (PR Newswire)
04:17PM	Inovio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Nov-03-25 08:05AM	INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults (PR Newswire) +6.38%
Oct-31-25 04:53PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Oct-27-25 08:05AM	INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire) +6.87%
04:05PM	Loading…
Oct-23-25 04:05PM	INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference (PR Newswire)
Oct-21-25 08:05AM	Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine (PR Newswire) -5.67%
Oct-02-25 08:05AM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Sep-25-25 08:05AM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:05AM	INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults (PR Newswire)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
08:05AM	INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-13-25 03:11AM	Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +14.09%
Aug-12-25 04:20PM	Inovio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Aug-11-25 06:55PM	Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:10AM	3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
08:05AM	Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) (PR Newswire)
Aug-07-25 10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-05-25 10:00AM	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Aug-04-25 04:05PM	INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-07-25 04:05PM	INOVIO to Present at Upcoming Scientific Conference (PR Newswire)
Jul-03-25 07:30AM	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire) -37.85%
Jul-02-25 04:16PM	INOVIO Announces Proposed Public Offering (PR Newswire)
Jul-01-25 07:00AM	Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development (GlobeNewswire)
May-14-25 12:43PM	Q1 2025 Inovio Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... (GuruFocus.com)
May-13-25 05:40PM	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:39PM	Inovio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Apr-30-25 08:05AM	INOVIO to Present at Upcoming Scientific and Investor Conferences (PR Newswire)
Apr-29-25 08:05AM	INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 (PR Newswire)
Apr-21-25 07:40AM	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
Apr-09-25 12:00PM	Inovio (INO) Upgraded to Buy: Here's What You Should Know (Zacks) +8.90%
08:05AM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-01-25 09:35AM	Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) (Zacks) -7.98%
Mar-19-25 03:02AM	Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -6.67%
Mar-18-25 10:15PM	Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript (Motley Fool)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (PR Newswire)
Mar-13-25 06:15PM	INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 (PR Newswire) -5.85% +5.18%
Mar-12-25 12:55PM	INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 (PR Newswire) +5.13%
Feb-12-25 09:55AM	Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher (Zacks) +12.11%
08:00AM	Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications (PR Newswire)
Feb-10-25 08:05AM	Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference (PR Newswire)
Jan-29-25 04:14PM	INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) -7.31%
Jan-09-25 08:04AM	INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments (PR Newswire)
Dec-13-24 07:00AM	INOVIO Announces Pricing of $30 Million Public Offering (PR Newswire) -38.30%
Dec-12-24 04:01PM	INOVIO Announces Proposed Public Offering (PR Newswire) -6.58%
Dec-03-24 08:00AM	New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial (PR Newswire)
Nov-29-24 04:02PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Nov-15-24 02:15AM	Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ... (GuruFocus.com) -10.59%
02:08AM	Where are they now? 4 biotechs that soared then crashed during the pandemic (Pharma Voice)
Nov-14-24 09:15PM	Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript (Motley Fool)
04:27PM	Inovio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Nov-13-24 08:00AM	Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial (PR Newswire)
Nov-06-24 04:05PM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
08:00AM	INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-21-24 08:00AM	INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP (PR Newswire)
Oct-09-24 05:38AM	Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Oct-02-24 04:15PM	INOVIO Reports Inducement Grants Under Inducement Plan (PR Newswire)
Oct-01-24 08:00AM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
Sep-17-24 04:30PM	INOVIO to Present at Upcoming Scientific Conference (PR Newswire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-09-24 02:30AM	Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-08-24 04:40PM	Inovio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Aug-01-24 04:05PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire) -6.00% -5.29%
Jul-25-24 04:05PM	Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 (PR Newswire)
08:00AM	INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 (PR Newswire)
Jul-12-24 10:09AM	Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK (Zacks)
09:28AM	Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-24 08:00AM	INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway (PR Newswire) +18.97%

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INO

Inovio Pharmaceuticals Inc

Upgrade your Finviz experience